Hims & Hers (HIMS) rose 4% premarket after JPMorgan initiated coverage with an 'Overweight' rating and $35 price target. The firm cited the Novo Nordisk partnership as a turning point, easing legal concerns. JPMorgan predicts a revenue rebound in H2 and more branded drug deals, offsetting competition from Amazon and others.